Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 21, 2020
Agreement enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland .